Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale. Anti-BCMA antibody-drug conjugate (ADC) Blenrep (belantamab ...
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results